Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 9-nitro-20(s)-camptothecin
2. 9-nitrocamptothecin
3. 9-nitrocamptothecin, (s)-isomer
4. Rfs 2000
5. Rfs-2000
6. Rfs2000
1. 9-nitrocamptothecin
2. 91421-42-0
3. 9-nitro-20(s)-camptothecin
4. Orathecin
5. 9-nc
6. Camptogen
7. Rfs 2000
8. Rfs-2000
9. (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
10. 86639-62-5
11. Nitrocamptothecin
12. Rubitecan [usan]
13. Chebi:90225
14. Rfs2000
15. Rubitecan [usan:inn]
16. Unii-h19c446xxb
17. 9-nitro-(20s)-camptothecin
18. H19c446xxb
19. 9-nitro-20-(s)-camptothecin
20. Dtxsid7046752
21. Rfs 2000;9-nitrocamptothecin
22. (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
23. 9nc
24. Ncgc00167969-01
25. (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
26. 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-10-nitro-, (4s)-
27. Rubitecanum
28. Inhaled Orathecin
29. C20h15n3o6
30. 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-nitro-
31. 1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-nitro-
32. Rubitecan (inhaled)
33. 9-nitro Camptothecin
34. Rubitecan [inn]
35. Rubitecan [mi]
36. Rubitecan (usan/inn)
37. L9nc
38. D0i5xo
39. D0y1fo
40. Rubitecan [mart.]
41. Rubitecan [who-dd]
42. Schembl8640
43. 9-nitrocamptothecin (9-nc)
44. Ethyl-hydroxy-nitro-[?]dione
45. Chembl77305
46. Rubitecan (inhaled), Supergen
47. Camptothecin, 9-nitro-20(s)
48. Dtxcid5026752
49. Vhxnkpbccmumsw-fqevstjzsa-n
50. Bcp06207
51. Ex-a4326
52. Tox21_112597
53. Bdbm50248354
54. Mfcd06656294
55. S2288
56. Akos015895332
57. Akos025149224
58. C20-h15-n3-o6
59. Db06159
60. St-2617
61. Ncgc00167969-02
62. Ncgc00167969-03
63. Ac-13389
64. Ac-25083
65. Ac-33157
66. As-14856
67. Hy-13744
68. Cas-91421-42-0
69. Cs-0007769
70. N0822
71. D04031
72. A847954
73. Q510113
74. Aerosolized Liposomal 9 Nitro-20 (s) Camptothecin
75. Q-100889
76. Brd-k79821389-001-01-9
77. (19s)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
78. (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3\',4\':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
| Molecular Weight | 393.3 g/mol |
|---|---|
| Molecular Formula | C20H15N3O6 |
| XLogP3 | 0.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 1 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 126 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 861 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
Rubitecan prevents DNA from unwinding during replication via DNA topoisomerase 1, therefore interfering with tumor growth.
ABOUT THIS PAGE
77
PharmaCompass offers a list of Rubitecan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rubitecan manufacturer or Rubitecan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rubitecan manufacturer or Rubitecan supplier.
PharmaCompass also assists you with knowing the Rubitecan API Price utilized in the formulation of products. Rubitecan API Price is not always fixed or binding as the Rubitecan Price is obtained through a variety of data sources. The Rubitecan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A N0822 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of N0822, including repackagers and relabelers. The FDA regulates N0822 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. N0822 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of N0822 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A N0822 supplier is an individual or a company that provides N0822 active pharmaceutical ingredient (API) or N0822 finished formulations upon request. The N0822 suppliers may include N0822 API manufacturers, exporters, distributors and traders.
click here to find a list of N0822 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
N0822 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of N0822 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right N0822 GMP manufacturer or N0822 GMP API supplier for your needs.
A N0822 CoA (Certificate of Analysis) is a formal document that attests to N0822's compliance with N0822 specifications and serves as a tool for batch-level quality control.
N0822 CoA mostly includes findings from lab analyses of a specific batch. For each N0822 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
N0822 may be tested according to a variety of international standards, such as European Pharmacopoeia (N0822 EP), N0822 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (N0822 USP).
